NCT03148756

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

Phase 2, Open-Label, Randomized, Multicenter Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Documented Infective Endocarditis

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will compare dalbavancin to standard of care (SOC) antibiotic therapy for the completion of therapy in patients with complicated bacteremia or infective endocarditis.

Conditions

• Endocarditis
• Bacteremia

Interventions

Type	Name	Description
DRUG	Dalbavancin	Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
DRUG	Standard of Care	Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.

Timeline

• Start date: 2017-05-12
• Primary completion: 2017-08-04
• Completion: 2017-08-04
• First posted: 2017-05-11
• Last updated: 2022-04-25
• Results posted: 2018-09-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study